Eli Lilly to acquire CrossBridge Bio in a deal valued up to $300 million
Eli Lilly agreed to acquire Houston-based CrossBridge Bio, a startup focused on antibody-drug conjugates, in a deal worth up to $300 million, expanding Lilly's biotech and ADC capabilities.